Novel immune assay for quantification of plasma protective capacity against oxidized phospholipids.

Bochkov, Valery; Schoenenberger, Andreas; Oskolkova, Olga; Toth, Ursula; Stöckl, Johannes; Majdic, Otto; Daci, Armond; Resink, Thérèse J; Erne, Paul; Philippova, Maria (2016). Novel immune assay for quantification of plasma protective capacity against oxidized phospholipids. Biomarkers in medicine, 10(8), pp. 797-810. Future Medicine 10.2217/bmm-2016-0096

Full text not available from this repository. (Request a copy)

AIM Oxidized phospholipids (OxPL) are the major pathogenic component of oxidized low-density lipoproteins (OxLDL). Endogenous anti-OxPL activity, defined as the ability to neutralize adverse effects of oxidized lipids, may have biomarker potential. METHODS & RESULTS Using two anti-OxPL monoclonal antibodies (commercial mAB-E06 and custom mAB-509) we developed a novel ELISA that measures the global capacity of plasma to inactivate OxPL. Preincubation of OxLDL with plasma inhibits its binding of anti-OxPL mABs. This phenomenon ('masking') reflects anti-OxPL plasma activity. A pilot clinical application of the assay revealed reduced anti-OxPL activity in hypertension, coronary artery disease, acute coronary syndrome and diabetes. CONCLUSION Inadequate anti-OxPL protection may contribute to cardiovascular disease and have biomarker potential in conditions associated with abnormal lipid peroxidation.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Geriatric Clinic

UniBE Contributor:

Schoenenberger, Andreas


600 Technology > 610 Medicine & health




Future Medicine




Rebecca Rufer

Date Deposited:

16 May 2017 07:14

Last Modified:

16 May 2017 07:14

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

ELISA; anti-oxidized phospholipid antibodies; anti-oxidized phospholipid defense; biomarker potential; cardiovascular disease; oxidized phospholipids


Actions (login required)

Edit item Edit item
Provide Feedback